The β-Lactams Strike Back: Ceftazidime-Avibactam.

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Gram-negative bacterial resistance to antibiotics is a critical global health concern.
• Emergence of multidrug-resistant (MDR) gram-negative pathogens necessitates novel therapeutic agents.
• Ceftazidime-avibactam combines ceftazidime with avibactam, a novel beta-lactamase inhibitor.

Purpose of the Study:

• To evaluate the efficacy and safety of ceftazidime-avibactam for treating complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs).
• To assess the expanded spectrum of activity of avibactam against various beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC, and Klebsiella pneumoniae carbapenemase (KPC).

Main Methods:

• Phase II clinical trials were conducted to compare ceftazidime-avibactam with existing treatments like imipenem-cilastatin for cUTIs and meropenem for cIAIs.
• In vitro and in vivo studies assessed the inhibitory activity of avibactam against a range of beta-lactamase enzymes.
• Pharmacodynamic analysis informed the selection of the approved dosage regimen.

Main Results:

• Ceftazidime-avibactam demonstrated comparable clinical and microbiologic success rates to imipenem-cilastatin in cUTI patients.
• In cIAI patients, ceftazidime-avibactam plus metronidazole showed similar clinical response rates to meropenem.
• Avibactam effectively inhibited class A and C beta-lactamases, expanding ceftazidime's spectrum to include resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Conclusions:

• Ceftazidime-avibactam is approved by the FDA for treating cUTIs and cIAIs in adult patients with limited treatment options.
• The drug represents a promising addition to the therapeutic armamentarium against MDR gram-negative bacteria.
• Further research is needed for highly resistant infections, and judicious use is crucial to maintain its effectiveness.